OverviewSuggest Edit

Adaptive Biotechnologies is a company developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its main product, immunoSEQ, uses a proprietary immune profiling assay to analyze T cells and B cells, critical components of the adaptive immune system’s defense against disease. The company develops a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. 

TypePublic
Founded2009
HQSeattle, US
Websiteadaptivebiotech.com
Employee Ratings4
Culture scoreB-

Latest Updates

Employees (est.) (Dec 2019)453(+31%)
Job Openings42
Revenue (FY, 2019)$85.1 M(+53%)
Share Price (Mar 2020)$19.7 (-28%)

Key People/Management at Adaptive Biotechnologies

Chad Robins

Chad Robins

Chief Executive Officer & Co-Founder, Director
Nancy Hill

Nancy Hill

Senior Vice President, Operations
Chad Cohen

Chad Cohen

Chief Financial Officer
Harlan Robins

Harlan Robins

Chief Scientific Officer & Co-Founder
Charles Sang

Charles Sang

Senior Vice President, Adaptive Diagnostics
Sean Nolan

Sean Nolan

Chief Technical Officer
Show more

Adaptive Biotechnologies Office Locations

Adaptive Biotechnologies has offices in Seattle, New York and South San Francisco
Seattle, US (HQ)
1551 Eastlake Ave E #200
New York, US
1460 Broadway
South San Francisco, US
2 Tower Pl #900
Show all (3)

Adaptive Biotechnologies Financials and Metrics

Adaptive Biotechnologies Revenue

Embed Graph
View revenue for all periods
Adaptive Biotechnologies's revenue was reported to be $85.07 m in FY, 2019
USD

Revenue (FY, 2019)

85.1m

Gross profit (FY, 2019)

62.8m

Gross profit margin (FY, 2019), %

73.8%

Net income (FY, 2019)

(68.6m)

EBIT (FY, 2019)

(78.4m)

Market capitalization (13-Mar-2020)

2.5b

Closing stock price (13-Mar-2020)

19.7

Cash (31-Dec-2019)

96.6m

EV

2.4b
Adaptive Biotechnologies's current market capitalization is $2.5 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

38.4m55.7m85.1m

Revenue growth, %

45%

Cost of goods sold

15.7m19.7m22.3m

Gross profit

22.8m36.0m62.8m
Quarterly
USDQ2, 2019Q3, 2019

Revenue

22.1m26.1m

Cost of goods sold

5.7m5.6m

Gross profit

16.4m20.5m

Gross profit Margin, %

74%79%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

83.3m55.0m96.6m

Accounts Receivable

5.6m4.8m12.7m

Prepaid Expenses

2.7m3.1m14.1m

Inventories

4.8m7.8m9.1m
Quarterly
USDQ2, 2019Q3, 2019

Cash

48.5m74.9m

Accounts Receivable

7.3m9.3m

Prepaid Expenses

4.0m10.0m

Inventories

8.0m8.7m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(42.8m)(46.4m)(68.6m)

Depreciation and Amortization

5.8m6.0m1.7m

Inventories

(2.7m)(3.0m)(1.2m)

Accounts Payable

(1.5m)2.2m6.1m
Quarterly
USDQ2, 2019Q3, 2019

Net Income

(34.0m)(48.0m)

Depreciation and Amortization

3.7m5.7m

Inventories

(166.0k)(829.0k)

Accounts Payable

1.3m3.1m
USDY, 2019

EV/EBIT

-31.1 x

EV/CFO

11.9 x

Revenue/Employee

212.9k

Financial Leverage

1.6 x
Show all financial metrics

Adaptive Biotechnologies Operating Metrics

FY, 2018

Immune Receptors Characteristics in Database

20 b

Partners

125

Product Lines

2
Show all operating metrics

Adaptive Biotechnologies Revenue Breakdown

Embed Graph

Adaptive Biotechnologies revenue breakdown by business segment: 59.2% from Sequencing revenue and 40.8% from Development revenue

Adaptive Biotechnologies Online and Social Media Presence

Embed Graph

Adaptive Biotechnologies Company Culture

  • Overall Culture

    B-

    75/100

  • CEO Rating

    A+

    90/100

  • Compensation

    D-

    49/100

  • Diversity

    D+

    61/100

Learn more on Comparably

Adaptive Biotechnologies News and Updates

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia

SEATTLE, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medi…

Adaptive Biotechnologies stock down 8.5% in premarket trade

Shares of Adaptive Biotechnologies Corp. fell 8.5% in premarket trade Wednesday after the company reported earnings that fell short of analysts' expectations and predicted lower-than-expected full-year revenue. Adaptive, which went public in June, reported late Tuesday a second-quarter loss of $…

Adaptive Biotechnologies stock tumbles after first earnings report since IPO

Adaptive Biotechnologies shares fell in after-hours trading Tuesday after the biotech company posted a wider-than-expected loss in its first earnings report since going public.

Adaptive Biotechnologies CEO Chad Robins on that crazy IPO and working with his older brother

MarketWatch spoke with Adaptive Biotechnologies’ Chief Executive Chad Robins about the IPO, what’s next for the company and what it’s like working with his older brother.

Forget Beyond Meat — Adaptive Biotechnologies just spiked 95% in its public trading debut, marking the year’s best post-IPO pop (ADPT)

Adaptive Biotechnologies went public on Thursday, jumping 95% above its offer price at the open. That marked the best post-IPO pop of the year for any company, on an offer-to-open basis. The Seattle-based biotech, which provides tests used to diagnose and treat diseases, began trading shortly afte…

Adaptive Biotechnologies rockets 94% in trading debut

Adaptive Biotechnologies rockets 94% in trading debut
Show more

Adaptive Biotechnologies Blogs

Adaptive Biotechnologies Announces Private Payor Coverage of clonoSEQ for Detecting and Monitoring MRD in Patients with Lymphoid Blood Cancers, Expanding Access to Over 140 million People in the United States

SEATTLE, Wash., June 20, 2019 — Adaptive Biotechnologies today announced that it has secured contractual agreements or positive medical policies for the clonoSEQ® Assay with several of the largest national private health insurers in the United States, as well as significant regional coverage, bringi…

Adaptive Biotechnologies Appoints Seasoned Biotechnology Executives Kevin Conroy and Michelle Griffin to Board of Directors

SEATTLE, Wash, May 30, 2019 — Adaptive Biotechnologies today announced Kevin Conroy, chairman and CEO of Exact Sciences Corporation, and Michelle Griffin, director Acer Therapeutics, Inc. and HTG Molecular Diagnostics, Inc., have been elected to the board of directors. Board member Arnold J. Levine,…

Adaptive Biotechnologies Frequently Asked Questions

  • When was Adaptive Biotechnologies founded?

    Adaptive Biotechnologies was founded in 2009.

  • Who are Adaptive Biotechnologies key executives?

    Adaptive Biotechnologies's key executives are Chad Robins, Nancy Hill and Chad Cohen.

  • How many employees does Adaptive Biotechnologies have?

    Adaptive Biotechnologies has 453 employees.

  • What is Adaptive Biotechnologies revenue?

    Latest Adaptive Biotechnologies annual revenue is $85.1 m.

  • What is Adaptive Biotechnologies revenue per employee?

    Latest Adaptive Biotechnologies revenue per employee is $187.8 k.

  • Who are Adaptive Biotechnologies competitors?

    Competitors of Adaptive Biotechnologies include Proteus Digital Health, Takeda Pharmaceutical and Kite Pharma.

  • Where is Adaptive Biotechnologies headquarters?

    Adaptive Biotechnologies headquarters is located at 1551 Eastlake Ave E #200, Seattle.

  • Where are Adaptive Biotechnologies offices?

    Adaptive Biotechnologies has offices in Seattle, New York and South San Francisco.

  • How many offices does Adaptive Biotechnologies have?

    Adaptive Biotechnologies has 3 offices.